A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2011
10/05/2011	CN102204671A Composition containing morus berry
10/05/2011	CN102204602A Lipid-lowering and antihypertensive health tea and preparation method thereof
10/05/2011	CN102204601A Blood sugar-reducing health-care tea and preparation method thereof
10/05/2011	CN101856450B Chinese medicinal composition for treating diabetic nephropathy
10/05/2011	CN101837060B Chinese medicine for adjusting hypertension, hyperlipidemia and hyperglycemia
10/05/2011	CN101785831B Preparation method of rice bran dietary fiber
10/05/2011	CN101732323B Application of low-dose ursolic acid as medicament for treating diabetic early nephropathy
10/05/2011	CN101687961B Crosslinked polyallylamine or acid addition salt thereof, and use thereof for medical purposes
10/05/2011	CN101669954B Ferrous fumarate folic acid dispersible tablet and preparation method thereof
10/05/2011	CN101658487B Glimepiride aqueous solution administration system and preparation method thereof
10/05/2011	CN101530469B Method for preparing effective component group of water soluble Chinese cassia tree
10/05/2011	CN101481404B Zymohydrolysis lactoprotein ferrous complex compound microcapsule iron supplement agent and preparation thereof
10/05/2011	CN101439058B Compound Chinese medicine gingko granule and preparation method thereof
10/05/2011	CN101401821B Bee pollen peptide slice and preparation method thereof
10/05/2011	CN101380129B Beverage for reducing weight, protect and strengthen health and production technique thereof
10/05/2011	CN101357182B Medicine containing dark plum for treating diabetes and preparation method thereof
10/05/2011	CN101323604B Novel PPAR alpha/beta dual agonist, preparation and use thereof
10/05/2011	CN101313892B Glipizide calcium alginate gel rubber pellet and preparation method thereof
10/05/2011	CN101297880B Active extract containing phlorizin and uses thereof
10/05/2011	CN101268848B Dew concentration beverage
10/05/2011	CN101240033B Fusion protein of insulin secretion accelerating peptide and human serum albumin, and preparation method thereof
10/05/2011	CN101229265B Antidiabetics and antiatheroscloresis medicine compounds and preparing method thereof
10/05/2011	CN101152285B Pharmaceutical composition of snakegourd fruit and whitethorn leaf
10/05/2011	CN101015575B Process for preparing bupleurum root dropping pills
10/05/2011	CN101007079B An extraction method of total flavones from hawthorn extract
10/04/2011	US8030517 CCR9 inhibitors and methods of use thereof
10/04/2011	US8030488 Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents
10/04/2011	US8030306 Azabicyclic heterocycles as cannabinoid receptor modulators
10/04/2011	US8030296 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
10/04/2011	US8030275 Methods for treating obesity using fibroblast growth factor-like polypeptides
10/04/2011	US8030271 Compositions and methods for buccal delivery of human growth hormone
10/04/2011	US8029832 Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
10/04/2011	US8029823 Controlled release and taste masking oral pharmaceutical composition
10/04/2011	US8029772 Free-flowing anionic surfactant, alkanolamide and electrolytemixture
10/04/2011	CA2673462C Solid oral dosage forms of valsartan
10/04/2011	CA2589059C Trace elements
10/04/2011	CA2494536C A 12-membered ring macrolide active substance
10/04/2011	CA2470539C Islet cells from human embryonic stem cells
10/04/2011	CA2447417C Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate
10/04/2011	CA2394117C Process for the preparation of arylethanolamine derivatives having anti-obesity and anti-diabetic properties
10/04/2011	CA2340103C Carbohydrate mixtures
09/2011
09/29/2011	WO2011119649A2 Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs
09/29/2011	WO2011119033A1 Low protein infant formula with increased essential amino acids
09/29/2011	WO2011119023A1 Low protein infant formula with increased essential amino acids
09/29/2011	WO2011118953A2 Composition for the prevention or treatment of obesity or lipid related metabolic deseases
09/29/2011	WO2011118810A1 Nutritional composition
09/29/2011	WO2011118804A1 Novel anti-cd98 antibody and use thereof
09/29/2011	WO2011117711A1 Pharmaceutical composition comprising a pyrimidineone derivative
09/29/2011	WO2011117706A1 Alr2 inhibitors and their synthesis from a natural source
09/29/2011	WO2011117559A1 Proangiogenic compositions, method for preparing same, and uses thereof
09/29/2011	WO2011117429A1 Cannabinoid quinone derivatives
09/29/2011	WO2011117401A1 Use of pcsk9 as a vaccine for lowering cholesterol
09/29/2011	WO2011117295A1 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amin0-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
09/29/2011	WO2011117254A1 Piperidine amides as modulators of the ghrelin receptor
09/29/2011	WO2011117163A1 Cyclopentyl - and cycloheptylpyrazoles as fxr modulators
09/29/2011	WO2011089525A3 Chia seed protein concentrate
09/29/2011	WO2011085979A4 Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
09/29/2011	WO2011060213A3 Preparation of sitagliptin and salts thereof
09/29/2011	WO2011056447A3 Methods and kits for preventing hypoglycemia
09/29/2011	WO2011043568A3 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
09/29/2011	WO2011035343A3 Phentermine liquid dosage form
09/29/2011	US20110238036 Sustained release delivery devices
09/29/2011	US20110238003 Method for systemic drug delivery through the nail
09/29/2011	US20110238000 Polymer-conjugated albumin hydrogels for controlled release of therapeutic agents
09/29/2011	US20110237792 Quinoline derivatives and their use as 5-ht6 ligands
09/29/2011	US20110237675 Pharmaceutical formulations
09/29/2011	US20110237673 Novel NIDDM Regimen
09/29/2011	US20110237669 Polyunsaturated Fatty Acids Interactions and Oxidative Stress Disorders
09/29/2011	US20110237666 Hydroxybutyrate ester and medical use thereof
09/29/2011	US20110237659 Chromenone derivatives as trpv3 antagonists
09/29/2011	US20110237650 Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
09/29/2011	US20110237649 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
09/29/2011	US20110237645 USE OF RNAi TECHNOLOGY TO INHIBIT ASIC3
09/29/2011	US20110237642 Process for Forming Amorphous Atorvastatin
09/29/2011	US20110237640 Pyrazole phenyl derivatives
09/29/2011	US20110237634 Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
09/29/2011	US20110237633 Small molecule modulators of hepatocyte growth factor (scatter factor) activity
09/29/2011	US20110237630 Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
09/29/2011	US20110237625 SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS
09/29/2011	US20110237613 Dha esters and use thereof in treatment and prevention of cardiovascular disease
09/29/2011	US20110237601 Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
09/29/2011	US20110237596 Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
09/29/2011	US20110237587 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same
09/29/2011	US20110237586 Biaryl compositions and methods for modulating a kinase cascade
09/29/2011	US20110237581 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
09/29/2011	US20110237575 Inhibitors of fatty acid binding protein (fabp)
09/29/2011	US20110237573 N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators
09/29/2011	US20110237569 SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS
09/29/2011	US20110237559 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1
09/29/2011	US20110237557 Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
09/29/2011	US20110237556 (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-HYDROXYVITAMIN D3
09/29/2011	US20110237544 Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use
09/29/2011	US20110237538 Treatment of lysosomal storage disorders and other proteostatic diseases
09/29/2011	US20110237533 Novel polyphenol compound
09/29/2011	US20110237532 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
09/29/2011	US20110237527 Sglt-2 inhibitors, methods of making them, and uses thereof
09/29/2011	US20110237526 Method for the preparation of a crystalline form
09/29/2011	US20110237524 Polymer conjugates of aod-like peptides
09/29/2011	US20110237510 Stabilized glucagon solutions
09/29/2011	US20110237505 Compositions and Methods for Treating Obesity and Diabetes

1 ... 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 ... 1298